ArticleJournal of surgical case reports2025
Invasive apocrine carcinoma of the breast-a surgeon's perspective on diagnosis, pitfalls, and evolving management options.
Article in Journal of surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive apocrine carcinoma (IAC) is a rare histologic subtype of breast carcinoma that commonly shows an ER/PR/HER2 triple negative phenotype with strong androgen receptor (AR) expression. We report a case of a 58 year old woman with an incidentally detected left breast lesion, treated with breast conserving surgery and sentinel lymph node biopsy. Final pathology revealed a 1.7 × 1 × 1 cm invasive carcinoma with apocrine morphology, clear margins and five negative sentinel nodes; IHC showed ER/PR/HER2 negativity, AR strongly positive (90%), and low proliferation (Ki-67 8%). The patient received whole breast radiotherapy followed by systemic chemotherapy with paclitaxel and carboplatin. This report emphasizes diagnostic pitfalls (including positron emission tomography limitations and cytology traps), practical intraoperative decision-making, axillary management tailored to indolent biology, and the emerging role of AR directed and genomic guided therapies from a surgeon's viewpoint. Awareness of these issues helps avoid overtreatment while preserving options for targeted systemic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.